BlackRock Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

BlackRock Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$8K	Hold	2,670	–	–	﹤0.01%	3597
2016 Q3	$16K	Hold	2,670	–	–	﹤0.01%	3499
2016 Q2	$8K	Sell	2,670 -4,350	-62%	-$17.9K	﹤0.01%	3624
2016 Q1	$38K	Hold	7,020	–	–	﹤0.01%	3246
2015 Q4	$83K	Sell	7,020 -2,481	-26%	-$28.4K	﹤0.01%	3001
2015 Q3	$78K	Buy	9,501 +394	+4%	+$4.55K	﹤0.01%	3189
2015 Q2	$127K	Buy	9,107 +6,295	+224%	+$115K	﹤0.01%	3071
2015 Q1	$68K	Buy	2,812 +271	+11%	+$6.09K	﹤0.01%	3171
2014 Q4	$42K	Buy	2,541 +1,097	+76%	+$12.7K	﹤0.01%	3321
2014 Q3	$18K	Sell	1,444 -31,666	-96%	-$477K	﹤0.01%	3524
2014 Q2	$747K	Sell	33,110 -53,618	-62%	-$972K	﹤0.01%	1705
2014 Q1	$2.45M	Buy	+86,728	New	+$3.22M	﹤0.01%	1132

Other funds holding DRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock Advisors's DRNA Position: Q4 2016 in Review

BlackRock Advisors held its Dicerna Pharmaceuticals, Inc. (DRNA) position steady in Q4 2016 at 2,670 shares worth $8K. The position accounts for ﹤0.01% of the portfolio, ranked #3597.

BlackRock Advisors first reported a position in DRNA in Q1 2014 and has held it in 12 quarters since. The position peaked at $2.45M in Q1 2014. 50 funds tracked by Wall St. Rank hold DRNA as of Q4 2016.

BlackRock Advisors held 2,670 shares of Dicerna Pharmaceuticals, Inc. worth $8K as of Q4 2016.
BlackRock Advisors left its Dicerna Pharmaceuticals, Inc. share count unchanged in Q4 2016.
Dicerna Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3597 holding.
BlackRock Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $2.45M in Q1 2014.
50 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.